Kunos Charles A, Capala Jacek
Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20850, USA.
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20850, USA.
Pharmaceuticals (Basel). 2020 Sep 30;13(10):287. doi: 10.3390/ph13100287.
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To better inform the design of therapeutic radiopharmaceutical trials, we reviewed academic scholarship discussing the clinical use of maintenance approaches to cancer treatment. Women with advanced-stage primary platinum-refractory or platinum-resistant ovarian carcinoma and their courses of treatment provide context for our discussion. Twenty-four (10%) out of 244 trials for women with ovarian carcinoma fit our search terms for maintenance trials. Five (2%) trials studied radiopharmaceuticals as switch maintenance. In our opinion, radiopharmaceutical switch maintenance merits further testing in prospective trials for women with advanced-stage primary platinum recurrent or refractory ovarian carcinoma.
转换维持治疗，或使用在先前癌症治疗过程中未使用过的替代治疗药物，已成为美国国立癌症研究所（NCI）癌症治疗评估计划（CTEP）药物开发序列中一项积极的临床研究及可获监管机构批准的途径。为了更好地指导治疗性放射性药物试验的设计，我们回顾了讨论癌症治疗维持方法临床应用的学术文献。晚期原发性铂类难治性或铂类耐药性卵巢癌女性患者及其治疗过程为我们的讨论提供了背景。在244项针对卵巢癌女性患者的试验中，有24项（10%）符合我们对维持治疗试验的检索词。5项（2%）试验将放射性药物作为转换维持治疗进行研究。我们认为，放射性药物转换维持治疗值得在晚期原发性铂类复发或难治性卵巢癌女性患者的前瞻性试验中进一步测试。
